Overview

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 in Combination With HLX10 in Patients With Advanced/Metastatic Solid Tumor

Status:
Not yet recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

This study is a open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 in combination with HLX10 with escalated doses in the treatment of patients with advanced/metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins